CRI Lifetree opens new early stage research facility

Tuesday, July 10, 2012 10:23 AM

CRI Lifetree, a specialized, multi-therapeutic early stage research company focused on pain, human abuse liability, psychiatry, neurology and diabetes, has opened a new state-of-the-art research facility in Marlton, N.J. The new site raises the company’s total bed count to 250 and adds capacity to conduct complex clinical trials.

“Because our facility is so close to Philadelphia, DIA gave us the opportunity to show many clients the site firsthand. The feedback was overwhelmingly positive!” said Larry Brownstein, head of corporate development, CRI Lifetree. “The recent visitors were pleased to see we have expanded our research space with this new, 60-bed, purpose-built facility.”

The additional bed space and added capabilities for conducting complex neurology, pediatrics and normal healthy patient studies comes at a time of considerable need for the industry. Other facility features include six beds dedicated to first-in-human studies. This space has an observation area to allow clinicians and sponsors the access needed. The new center also has separate areas for elderly and pediatric populations. The 21,000-square-foot building adds to CRI Lifetree’s two other facilities in Philadelphia and Salt Lake City.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs